Sanofi India has received a Rs 16.40 crore GST show cause notice from Gujarat tax authorities for the 2022-23 fiscal year. The notice cites discrepancies in E-Way bills, turnover reconciliations, and input tax credit claims. Management is currently reviewing the demand with tax advisors and does not expect any material adverse impact on the company's financial or operational health.
Sanofi India Faces Rs 16.40 Crore GST Demand
Total demand includes tax, interest, and penalties of Rs 16.40 crore.
Company maintains no material adverse impact expected on financial operations.
Reader Takeaway: This is a routine tax reconciliation dispute; management remains confident, but watch for further regulatory developments.
What just happened
Sanofi India Limited received a Show Cause Notice on September 28, 2026, from the State Tax Officer in Ahmedabad, Gujarat. The notice pertains to GST discrepancies for the 2022-23 financial year, covering tax, interest, and penalties totaling Rs 16.40 crore.
Why this matters
The authorities identified gaps between E-Way bill values and GSTR-1 filings, as well as inconsistencies in turnover reconciliations between GSTR-9C and GSTR-1. Furthermore, the notice alleges issues with the reversal of input tax credits and the eligibility of certain claims. For shareholders, this represents a regulatory process that requires legal and financial scrutiny to resolve.
Management Commentary
Sanofi India is currently consulting with tax experts to draft a formal response. The company has publicly stated that it does not foresee this specific demand causing any negative impact on its ongoing operations or financial standing.
What to track next
Investors should monitor future exchange filings to see if the company contests the demand in appellate forums or if the tax authorities adjust the liability following the company’s submission.